Psilocybin vs. Ketamine Therapy: Evidence, Cost, and Access
A clinical comparison of two psychedelic-assisted treatments for depression — how they work differently, what the evidence shows, how sessions compare, and who each treatment is best suited for in 2026.
Chief Bear · Last updated: · 10 min read
At a Glance
Both psilocybin therapy and ketamine treatment show clinical effectiveness for depression, but differ fundamentally in legal status, mechanism, session length, and durability of effect. Ketamine is FDA-approved, available nationwide, and acts within hours. Psilocybin is legal only in Oregon and Colorado, requires 4–8 hour sessions, and may produce effects lasting 6–12 months from just 1–3 treatments. Neither is covered by most health insurance.
| Factor | Psilocybin Therapy | Ketamine / Esketamine |
|---|---|---|
| Legal status (US) | Schedule I — legal in Oregon & Colorado only | FDA-approved (esketamine/Spravato); available nationwide |
| Mechanism | Serotonin 5-HT2A agonist; promotes neuroplasticity | NMDA glutamate receptor antagonist; rapid synaptic changes |
| Session length | 4–8 hours per session | 40–60 minutes per infusion |
| Number of sessions | 1–3 sessions total | 6 infusions over 2–3 weeks; often ongoing |
| Onset of effect | Days to 1 week post-session | Hours to days (very rapid) |
| Durability | 6–12+ months from 1–2 sessions (Davis et al., 2023) | 4–8 weeks; often requires maintenance |
| Remission rate | 58% at 12 months (Johns Hopkins, 2023) | ~27% at 4 weeks in FDA esketamine trials (2019) |
| Insurance coverage | Not covered | Esketamine partially covered; infusions generally not |
| Typical cost | $1,500–$3,500 full program | $2,000–$4,500 for 6 infusions; esketamine varies |
| Addiction potential | Not physically addictive | Ketamine has known addiction potential; esketamine monitored |
| Requires facilitator | Yes — licensed facilitator required by law | Yes — administered in clinic; esketamine requires observation |
Clinical Evidence: What the Trials Show
Both treatments have Phase II/III clinical trial support for depression. Psilocybin trial data shows higher long-term remission rates but from smaller studies. Esketamine (Spravato) is FDA-approved based on larger Phase III trials. Directly comparing the two is complicated because trials differ in design, population, and endpoints.
Psilocybin: Key Trials
Psilocybin has received FDA Breakthrough Therapy designation for treatment-resistant depression (2018) and major depressive disorder (2019). Phase III trials are currently underway with Compass Pathways. The existing evidence base consists primarily of Phase II randomized controlled trials — rigorous but smaller than typical FDA approval populations.
Ketamine / Esketamine: Key Trials
Esketamine (Spravato), the S-enantiomer of ketamine, was FDA-approved in 2019 for treatment-resistant depression based on Phase III clinical trials. IV racemic ketamine is widely used off-label for depression, though it lacks its own FDA approval for that indication. The speed of response — often within hours — is ketamine's most clinically distinctive feature, particularly valuable in acute settings or when rapid symptom relief is needed.
Psilocybin trial data shows higher long-term remission (58% at 12 months) but from Phase II populations. Esketamine is FDA-approved based on larger Phase III trials showing ~27% remission at 4 weeks, with the key advantage of rapid onset. Direct head-to-head comparisons do not yet exist.
How Each Treatment Works
Psilocybin and ketamine target different receptor systems and produce different neurological effects. Psilocybin disrupts the default mode network and promotes lasting neuroplasticity through serotonin 5-HT2A agonism. Ketamine produces rapid antidepressant effects through NMDA receptor blockade, increasing glutamate activity and promoting fast synaptic changes that may explain its speed of action.
Psilocybin: Serotonergic Neuroplasticity
Psilocybin is converted in the body to psilocin, which binds powerfully to serotonin 5-HT2A receptors concentrated in the prefrontal cortex. This binding dramatically reduces activity in the default mode network (DMN) — the brain's self-referential "rumination center" that is chronically overactive in depression — while simultaneously increasing connectivity across brain regions that rarely communicate in normal states.
Beyond the acute session, psilocybin promotes neuroplasticity — it stimulates the growth of new dendritic connections (synaptic spines) in the prefrontal cortex (Ly et al., Cell Reports, 2018). This structural rewiring helps explain why antidepressant effects persist for months after just one or two doses. The psychological depth of the session itself — the emotional processing and insight that occurs — is considered an integral part of the therapeutic mechanism, not a side effect.
Ketamine: Glutamate-Driven Rapid Relief
Ketamine blocks NMDA receptors, which regulate glutamate — the brain's primary excitatory neurotransmitter. This blockade triggers a cascade that increases AMPA receptor activity, releases BDNF (brain-derived neurotrophic factor), and activates mTOR pathways, rapidly promoting synaptic growth in the prefrontal cortex (Duman et al., Nature, 2019). The speed of this mechanism explains ketamine's characteristic rapid-onset antidepressant effect — often measurable within hours of treatment.
Ketamine's mechanism does not involve the kind of prolonged psychological processing that characterizes psilocybin therapy. The antidepressant effect appears to be primarily pharmacological rather than psychotherapeutically mediated, though adjunctive therapy is increasingly recommended to support and maintain gains.
Psilocybin's mechanism involves disrupting rigid neural patterns and catalyzing lasting structural rewiring — effects that build over days and persist for months. Ketamine's mechanism produces rapid but shorter-lived synaptic changes, explaining its faster onset and more frequent maintenance requirement.
Session Structure: What to Expect
Psilocybin Therapy: A Full-Day Commitment
Psilocybin therapy follows a three-phase structure: preparation (1–4 weeks of therapy sessions), the dosing session itself (4–8 hours in a supervised therapeutic setting), and integration (weeks of follow-up therapy). Most protocols use 1–3 dosing sessions total. The entire program spans 4–12 weeks.
- Preparation (1–4 weeks): Multiple sessions with a licensed facilitator to establish trust, set intentions, and prepare for the psychological experience. This phase is considered clinically essential — outcomes correlate with preparation quality.
- Dosing session (4–8 hours): Conducted in a purpose-designed therapeutic setting — typically a comfortable, non-clinical room with soft lighting, music, and continuous facilitator presence. The patient is encouraged to lie down, wear eye shades, and engage inwardly with the experience rather than speak throughout.
- Integration (2–6+ sessions): Post-session therapy to process insights, anchor behavioral changes, and monitor wellbeing during the neuroplasticity window. Research suggests this phase significantly affects long-term outcomes (Davis et al., 2021).
Ketamine Treatment: Shorter, Repeated Infusions
Ketamine infusions last 40–60 minutes and are typically administered in a reclining chair in a clinical setting. Patients are conscious but dissociative during the infusion — the experience is significantly different in character from a psilocybin session. Standard protocols involve 6 infusions over 2–3 weeks for the initial treatment series. Esketamine (Spravato) is administered as a nasal spray in a certified healthcare setting with a 2-hour observation period.
Maintenance infusions — typically every 4–8 weeks — are usually required to sustain antidepressant effects after the initial series. Unlike psilocybin, there is no established standard "integration therapy" component, though many clinicians are incorporating it as evidence for adjunctive therapy grows.
Psilocybin requires a much larger time commitment per session (4–8 hours) but far fewer total sessions (1–3 for most protocols). Ketamine sessions are brief and frequent. Psilocybin also requires a dedicated preparation and integration component that is absent in most ketamine protocols.
Legal Access in 2026
Ketamine therapy is available nationwide in the US. Psilocybin therapy is legal only in Oregon and Colorado. Both are available through retreat programs abroad (psilocybin: Jamaica, Netherlands, Mexico; ketamine: widely available internationally). Clinical trials may provide free supervised access to psilocybin for qualifying patients.
Psilocybin Access
- Oregon: Licensed service centers operating since June 2023 under Oregon Psilocybin Services. No residency requirement. Facilitator directory: Oregon Health Authority website.
- Colorado: Natural Medicine Access Program launched June 2025. Adults 21+. Facilitator directory: Colorado DORA Natural Medicine Division.
- International retreats: Legal psilocybin retreat programs operate in Jamaica, the Netherlands, and Mexico. See PsyBear's Retreats Directory.
- Clinical trials: Multiple Phase II and III trials are actively enrolling, some offering free access. Search ClinicalTrials.gov for "psilocybin depression."
Ketamine Access
- Ketamine infusion clinics: Private clinics operating in all major US cities. No prescription required for IV ketamine; a referral or intake assessment is typically needed.
- Esketamine (Spravato): FDA-approved; administered in a certified healthcare setting under a Risk Evaluation and Mitigation Strategy (REMS) program. Requires a prescription. Partially covered by some insurance plans for qualifying diagnoses.
- Telehealth ketamine: Several platforms offer at-home ketamine lozenges with telehealth supervision. These are legal but carry less oversight than in-clinic protocols.
Cost Comparison
A complete psilocybin program in Oregon typically costs $1,500–$3,500 (not covered by insurance). A ketamine infusion series typically costs $2,000–$4,500 for six sessions (not typically covered by insurance for infusions; esketamine may be partially covered). Over time, ketamine maintenance sessions may make the cumulative cost substantially higher.
| Cost item | Psilocybin Therapy | Ketamine / Esketamine |
|---|---|---|
| Initial program cost | $1,500–$3,500 (Oregon/CO full program) | $2,000–$4,500 (6 infusion series) |
| Maintenance cost | Typically none — effects last 6–12 months; booster if needed | $400–$800 per maintenance session every 4–8 weeks |
| Annual cost estimate | $1,500–$3,500 (one-time program) | $7,000–$15,000+ (initial + 6–8 maintenance sessions per year) |
| Insurance coverage | Not covered | Esketamine: partial coverage possible; infusions: generally not covered |
| Financial assistance | Oregon Psilocybin Access Fund (sliding scale) | Manufacturer coupons (Spravato); some clinics offer payment plans |
The cumulative cost advantage of psilocybin becomes more pronounced over time: while the upfront cost is comparable to a ketamine series, psilocybin's effect durability (6–12 months from 1–2 sessions) means fewer repeat treatments. Patients who require ongoing ketamine maintenance may spend significantly more annually.
Who Should Consider Each Treatment
Ketamine may be preferable when speed matters most — acute suicidality, rapid relief, or when psilocybin is legally inaccessible. Psilocybin may be preferable for patients willing to invest in a deeper therapeutic process and who want to minimize ongoing treatment burden. Neither is appropriate for all patients. A licensed clinician should guide the decision.
Ketamine May Be a Better Fit If:
- Speed is urgent: Ketamine produces antidepressant effects within hours — clinically valuable in acute settings or when rapid relief is needed
- You live outside Oregon or Colorado: Ketamine is available nationwide; psilocybin therapy requires travel or enrollment in a trial
- Insurance coverage matters: Esketamine may be partially covered for qualifying diagnoses; psilocybin therapy is not covered
- You prefer a shorter session format: Ketamine infusions last 40–60 minutes; psilocybin sessions last 4–8 hours
- You prefer a primarily pharmacological approach: Ketamine does not require the extended psychological process of psilocybin therapy
Psilocybin May Be a Better Fit If:
- Long-term durability is a priority: Evidence suggests effects from 1–2 sessions persist for 6–12 months, reducing the treatment burden significantly over time
- You want to minimize ongoing treatment frequency: A single psilocybin program (1–3 sessions) may provide relief that ketamine requires monthly maintenance to sustain
- You're open to a psychological process as part of the treatment: Psilocybin therapy uses the depth of the psychological experience as part of the mechanism — preparation and integration are therapeutic components, not just context
- You're in Oregon or Colorado (or can travel): Legal supervised psilocybin therapy requires access to a licensed service center in those states
Contraindications for Both
Both psilocybin and ketamine carry contraindications that require evaluation by a licensed clinician:
- Psilocybin: Contraindicated with personal/family history of schizophrenia, bipolar I, or psychotic spectrum disorders; current lithium use; pregnancy. SSRIs must be tapered before sessions.
- Ketamine: Contraindicated with active psychosis or mania; uncontrolled hypertension; personal history of ketamine misuse or substance use disorder involving dissociatives. Use with caution in patients with active suicidal ideation who lack strong social support.
This comparison is educational. Neither psilocybin therapy nor ketamine treatment should be started without a full psychiatric evaluation and guidance from a licensed healthcare provider. Psilocybin outside of licensed Oregon/Colorado programs or clinical trials is illegal under U.S. federal law.
Key Takeaways
- Both psilocybin and ketamine show clinical effectiveness for depression, but evidence bases differ: psilocybin has stronger long-term remission data (58% at 12 months); esketamine is FDA-approved based on Phase III trials (~27% remission at 4 weeks).
- They work through completely different mechanisms: psilocybin via serotonin 5-HT2A agonism and DMN disruption; ketamine via NMDA antagonism and glutamate cascade. Ketamine produces faster symptom relief; psilocybin produces more durable effects.
- Psilocybin sessions last 4–8 hours; ketamine infusions last 40–60 minutes. Psilocybin requires fewer total sessions (1–3); ketamine typically requires a series of 6 plus ongoing maintenance.
- Ketamine is available nationwide; psilocybin therapy is legal only in Oregon and Colorado. Both cost $1,500–$4,500 for initial treatment; ketamine maintenance costs can be substantially higher over time.
- No direct head-to-head clinical trial comparing psilocybin and ketamine for depression has been published. Treatment selection should be guided by a licensed clinician based on individual diagnosis, access, and goals.